Shares of biotech giant AbbVie (NYSE: ABBV) gained a healthy 15% in September, according to data from S&P Global Market Intelligence.
The spark? AbbVie's shares perked up after the company's presentation at the Morgan Stanley Healthcare Conference on Sept. 10. While the company didn't reveal anything new during this presentation, CEO Richard Gonzalez's comments about the upcoming Allergan (NYSE: AGN) acquisition, as well as how the company plans to create value as Humira goes off patent, appear to have gone a long way toward reassuring investors.
Image source: Getty Images.